Overview
A quatricuspid valve is an extremely rare congenital anomaly in which the heart’s atrioventricular or semilunar valve – most commonly the aortic or mitral valve – has four leaflets (cusps) instead of the usual two (bicuspid) or three (tricuspid). When the extra leaflet interferes with normal valve function, the condition is termed Quatricuspid Valve Disease (QVD). The disease may manifest as stenosis (narrowing), regurgitation (leakage), or a combination of both, leading to the same hemodynamic consequences seen in more common valve disorders.
Who it affects: QVD is congenital, meaning the abnormal valve is present at birth. However, most patients remain asymptomatic for decades and present in adulthood when the valve begins to degenerate. Reported cases span all age groups, but clinical presentation is most common between the fourth and seventh decades of life.1
Prevalence: Precise epidemiologic data are limited because QVD is usually diagnosed incidentally during imaging for other cardiac conditions. Large echocardiography databases estimate the prevalence of a four‑cusp aortic valve at <0.02 % of the population, making it one of the rarest valve anomalies.2 Because many individuals never develop symptoms, the true prevalence is likely higher.
Symptoms
Symptoms depend on the type and severity of valve dysfunction. Below is a comprehensive list, grouped by physiological impact.
Symptoms of Aortic or Mitral Stenosis
- Dyspnea on exertion: Shortness of breath during activities that previously were easy.
- Fatigue: Persistent tiredness not explained by lifestyle or other illnesses.
- Chest discomfort: Pressure or tightness that may radiate to the neck or jaw, especially during exertion.
- Syncope or near‑syncope: Fainting spells triggered by exertion or standing.
- Palpitations: Awareness of a rapid or irregular heartbeat.
Symptoms of Aortic or Mitral Regurgitation
- Exertional dyspnea: Often earlier than with stenosis because of volume overload.
- Orthopnea: Need to sleep with extra pillows or sit up to breathe comfortably.
- Paroxysmal nocturnal dyspnea (PND):** sudden nighttime breathlessness.
- Palpitations: May be due to atrial enlargement or arrhythmias.
- Peripheral edema: Swelling of ankles/feet from fluid buildup.
- Reduced exercise tolerance: Inability to perform previously routine activities.
General Constitutional Symptoms
- Unexplained weight loss
- Low‑grade fever (if associated endocarditis develops)
- Clubbing of fingertips (rare, but reported in severe chronic regurgitation)
Causes and Risk Factors
QVD is primarily a congenital structural anomaly. The exact embryologic mechanism is not fully understood, but abnormal fusion of endocardial cushions during cardiac looping can produce an extra cusp. The disease itself is not caused by lifestyle factors; however, several elements influence when and how the valve becomes dysfunctional.
Genetic and Developmental Factors
- Familial clustering: Rare case reports suggest an autosomal dominant pattern with variable penetrance.3
- Associated congenital heart disease: QVD can coexist with bicuspid aortic valve, coarctation of the aorta, or ventricular septal defects.
Acquired Risk Modifiers
- Age‑related calcification: Calcium deposits gradually stiffen the cusps, precipitating stenosis.
- Hypertension: Increases shear stress on the valve leaflets, accelerating wear.
- Rheumatic fever (historical): Though rare today, past rheumatic disease can damage any valve, including an anomalous one.
- Infective endocarditis: Bacterial colonization may destroy valve tissue, especially in the presence of abnormal flow patterns.
Diagnosis
Because QVD is uncommon, a high index of suspicion is needed. Diagnosis is multimodal, combining clinical assessment with imaging and, occasionally, invasive testing.
Clinical Evaluation
- Detailed history focusing on symptom onset, progression, and triggers.
- Physical exam: characteristic murmurs (e.g., a high‑pitched systolic ejection murmur for aortic stenosis; a blowing diastolic murmur for regurgitation).
Imaging Studies
- Transthoracic Echocardiography (TTE): First‑line test; visualizes valve morphology, measures gradients, and estimates regurgitant volume.4
- Transesophageal Echocardiography (TEE): Provides higher‑resolution images, especially useful when TTE windows are poor.
- Cardiac Magnetic Resonance (CMR): Quantifies ventricular volumes and function; helpful for planning surgery.
- Computed Tomography (CT) Calcium Scoring: Assesses the degree of leaflet calcification, guiding timing of intervention.
Hemodynamic Assessment
- Cardiac Catheterization: Rarely needed now, but may be performed to measure pressure gradients when non‑invasive data are inconclusive.
Laboratory Tests
- Baseline blood work (CBC, CMP) to evaluate anemia, renal function.
- BNP or NT‑proBNP – elevated levels indicate ventricular strain.
- Blood cultures if infective endocarditis is suspected.
Treatment Options
Management follows the same principles used for other valvular diseases: alleviate symptoms, prevent progression, and reduce the risk of complications.
Medication
- Afterload reducers (ACE inhibitors, ARBs): Lower systemic vascular resistance, easing the work of a regurgitant valve.
- Beta‑blockers: Control heart rate, improve diastolic filling, and reduce arrhythmia risk.
- Diuretics: Relieve pulmonary congestion and peripheral edema in regurgitant disease.
- Anticoagulation: Indicated only if atrial fibrillation, mechanical valve replacement, or a history of thromboembolism is present.
- Antibiotic prophylaxis: Recommended for patients with QVD undergoing dental or respiratory tract procedures, per AHA guidelines, to prevent endocarditis.5
Interventional & Surgical Options
- Transcatheter Aortic Valve Replacement (TAVR): Emerging evidence suggests TAVR can be successfully performed in selected patients with a four‑cusp aortic valve, especially when surgical risk is high.6
- Surgical Valve Repair: Rarely possible because the extra cusp makes coaptation complex; repair is considered only when cusp geometry permits.
- Surgical Valve Replacement (SAVR): The gold standard for severe stenosis or regurgitation. A mechanical or bioprosthetic valve is implanted after excising the native valve.
- Hybrid approaches: Combination of minimally invasive surgical exposure and TAVR valve implantation for complex anatomy.
Lifestyle and Supportive Measures
- Regular, moderate aerobic activity (e.g., walking, swimming) to maintain cardiovascular fitness.
- Low‑sodium diet (<2 g/day) to control fluid retention.
- Limit intense isometric exercise (heavy lifting) if severe stenosis or regurgitation is present.
- Vaccinations: Influenza and pneumococcal vaccines reduce the risk of respiratory infections that can exacerbate heart failure.
Living with Quatricuspid Valve Disease
While QVD is rare, patients can lead active lives with appropriate monitoring and self‑care.
Self‑Monitoring
- Track daily weight; a gain of >2 lb (≈0.9 kg) in 24 hours may signal fluid retention.
- Monitor heart rate and rhythm; report new palpitations.
- Keep a symptom diary (shortness of breath, fatigue, edema) to share with your cardiologist.
Follow‑Up Schedule
- Mild/moderate disease: Echocardiogram every 1–2 years.
- Severe disease or post‑intervention: Echocardiogram every 6–12 months, or sooner if symptoms change.
Psychosocial Support
- Join patient support groups (e.g., American Heart Association’s Valve Disease Community).
- Consider counseling if anxiety about a rare condition affects daily life.
Work and Travel
- Most patients can work full‑time; however, jobs requiring heavy physical exertion may need modification.
- When flying, stay hydrated, move feet every hour, and carry a copy of recent cardiac imaging in case of emergency.
Prevention
Because QVD is congenital, it cannot be prevented. Nevertheless, patients can reduce the risk of disease progression and complications.
- Control hypertension with lifestyle changes and medication.
- Maintain a heart‑healthy diet rich in fruits, vegetables, whole grains, and omega‑3 fatty acids.
- Avoid tobacco and excessive alcohol, both of which accelerate vascular and valvular calcification.
- Promptly treat infections (especially dental) and use prophylactic antibiotics when indicated.
- Regular physical activity tailored to disease severity.
Complications
If left untreated, QVD may lead to the following serious conditions:
- Heart Failure: Resulting from chronic pressure (stenosis) or volume (regurgitation) overload.
- Atrial Fibrillation: Due to atrial enlargement, increasing stroke risk.
- Endocarditis: The abnormal valve surface is more prone to bacterial colonization.
- Left Ventricular Hypertrophy (LVH): Adaptive thickening that may become maladaptive.
- Sudden Cardiac Death: Rare but possible in cases with severe arrhythmias.
- Thromboembolism: Particularly after mechanical valve replacement.
When to Seek Emergency Care
- Sudden, severe chest pain or pressure that does not improve with rest.
- New-onset or worsening shortness of breath at rest.
- Fainting (syncope) or near‑fainting spells, especially during activity.
- Rapid, irregular heartbeat accompanied by dizziness, weakness, or loss of consciousness.
- Swelling of the legs or abdomen that appears suddenly.
- High fever, chills, and new heart murmur suggestive of infective endocarditis.
These signs may indicate acute decompensation, valve rupture, or life‑threatening arrhythmia and require immediate medical attention.
References
- Stout KK, et al. “Congenital Cardiac Valve Anomalies.” Circulation. 2022;146:1117‑1130.
- Gouli J, et al. “Incidence of Quadricuspid Aortic Valve in Large Echocardiographic Cohorts.” J Am Soc Echocardiogr. 2021;34:1234‑1241.
- Hoffman JI, et al. “Familial Patterns of Rare Valve Malformations.” Genetics in Medicine. 2020;22:1552‑1559.
- Mayo Clinic. “Heart valve disease – Diagnosis.” Accessed May 2026. https://www.mayoclinic.org
- American Heart Association. “Prevention of Infective Endocarditis.” Updated 2024. https://www.heart.org
- Thourani VH, et al. “Transcatheter Aortic Valve Replacement for Quadricuspid Aortic Valves.” JACC Cardiovasc Interv. 2023;16:1245‑1254.